{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:58:04Z","timestamp":1770263884032,"version":"3.49.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,12]]},"abstract":"<jats:p>\n                    Multiple Sclerosis (MS), one of the most common neurological diseases, plays a major role in the ailments of adults. Studies on the role of homocysteine (Hcy) and folic acid in causing cognitive disorders in patients diagnosed with MS are still ongoing. This study aimed to evaluate the serum levels of folic acid and Hcy related to cognitive impairment in patients with multiple sclerosis. This prospective clinical study was conducted on 57 patients diagnosed with MS who were referred to Firoozgar Hospital, Tehran, Iran (Between November 2019 and September 2021). Demographic information and clinical characteristics of enrolled patients were recorded in a predesigned checklist. These characteristics were comprised of outcomes related to the Brief International Cognitive Assessment for MS, and the patient\u2019s Hcy and acid folic levels. Data were analyzed using SPSS version 25. Out of 57 enrolled patients, 39 subjects (68.4%) were female and 18 subjects (31.6%) were male, with a mean age of 36.87\u2005\u00b1\u20059.40 years old. In terms of disease time span, there was a mean duration of 3.80\u2005\u00b1\u20054.94 years (range: 1\u201323 years). There were no significant differences between the mean score of Brief International Cognitive Assessment for MS scale with patient\u2019s sex (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    value: .88), and disease duration of patients (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    value: .86). There was no significant relationship between the serum levels of acid folic and Hcy with cognitive impairment (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    value\u2005&gt;\u2005.05). The study results revealed that there were no significant relationships between the folic acid, Hcy levels, disease duration, and the type of MS disease with the severity of cognitive impairment. More randomized controlled clinical trials are needed to confirm the relationships between the folic acid and Hcy levels with cognitive impairment in patients with MS.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000038680","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T15:09:27Z","timestamp":1720796967000},"page":"e38680","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Relationship between serum levels of folic acid and homocysteine with cognitive impairment in patients diagnosed with multiple sclerosis"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4529-8766","authenticated-orcid":false,"given":"Azadeh","family":"Imeni Kashan","sequence":"first","affiliation":[{"name":"School of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Mirzaasgari","sequence":"additional","affiliation":[{"name":"Department of Neurology, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabnam","family":"Nouri Shirazi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Institute for Cognitive Science Studies, Tehran, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20260204","doi-asserted-by":"crossref","first-page":"A387","DOI":"10.1016\/j.autrev.2009.11.010","article-title":"Multiple sclerosis: geoepidemiology, genetics and the environment.","volume":"9","author":"Milo","year":"2010","journal-title":"Autoimmun Rev"},{"key":"R3-20260204","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1017\/S0317167100012488","article-title":"Assessment of outcome predictors after first attack of optic neuritis.","volume":"38","author":"Mamarabadi","year":"2011","journal-title":"Can J Neurol Sci"},{"key":"R5-20260204","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/B978-0-7506-7525-3.50092-3","article-title":"Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system.","volume":"2","author":"Lublin","year":"2008","journal-title":"Neurol Clin Pract"},{"key":"R7-20260204","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis.","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"R8-20260204","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1474-4422(15)00018-6","article-title":"Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.","volume":"14","author":"Palace","year":"2015","journal-title":"Lancet Neurol"},{"key":"R9-20260204","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000342779","article-title":"Incidence and prevalence of multiple sclerosis in the Americas: a systematic review.","volume":"40","author":"Evans","year":"2013","journal-title":"Neuroepidemiology"},{"key":"R10-20260204","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology.","volume":"9","author":"Koch-Henriksen","year":"2010","journal-title":"Lancet Neurol"},{"key":"R11-20260204","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/brain\/aws099","article-title":"The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.","volume":"135","author":"Wallin","year":"2012","journal-title":"Brain"},{"key":"R13-20260204","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"R14-20260204","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions.","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"R15-20260204","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/postgradmedj-2017-135397","article-title":"Association between circulating leptin levels and multiple sclerosis: a systematic review and meta-analysis.","volume":"94","author":"Xie","year":"2018","journal-title":"Postgrad Med J"},{"key":"R16-20260204","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1474-4422(06)70598-1","article-title":"Vitamin B12, folic acid, and the nervous system.","volume":"5","author":"Reynolds","year":"2006","journal-title":"Lancet Neurol"},{"key":"R17-20260204","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.clineuro.2013.05.007","article-title":"Homocysteine, vitamin B12 and folate levels in Iranian patients with multiple sclerosis: a case control study.","volume":"115","author":"Moghaddasi","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"R18-20260204","doi-asserted-by":"crossref","first-page":"e46496","DOI":"10.1371\/journal.pone.0046496","article-title":"The relationship between associative learning, transfer generalization, and homocysteine levels in mild cognitive impairment.","volume":"7","author":"Moustafa","year":"2012","journal-title":"PLoS One"},{"key":"R19-20260204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3988\/jcn.2014.10.4.281","article-title":"Hyperhomocysteinemia and neurologic disorders: a review.","volume":"10","author":"Ansari","year":"2014","journal-title":"J Clin Neurol"},{"key":"R20-20260204","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2018.07.011","article-title":"Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.","volume":"323","author":"Kvistad","year":"2018","journal-title":"J Neuroimmunol"},{"key":"R21-20260204","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"R22-20260204","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archneur.55.11.1449","article-title":"Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease.","volume":"55","author":"Clarke","year":"1998","journal-title":"Arch Neurol"},{"key":"R23-20260204","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/ajcn\/80.1.114","article-title":"Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia.","volume":"80","author":"Quadri","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"R24-20260204","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/jnnp.2007.131482","article-title":"Changes in folate, vitamin B12 and homocysteine associated with incident dementia.","volume":"79","author":"Kim","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R25-20260204","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/ajcn\/82.3.636","article-title":"Homocysteine and folate as risk factors for dementia and Alzheimer disease.","volume":"82","author":"Ravaglia","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"R26-20260204","doi-asserted-by":"crossref","first-page":"532","DOI":"10.30773\/pi.2019.05.29","article-title":"Normal-but-low serum folate levels and the risks for cognitive impairment.","volume":"16","author":"Jang","year":"2019","journal-title":"Psychiatry Investig"},{"key":"R27-20260204","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/nu9070725","article-title":"Plasma homocysteine and serum folate and vitamin B12 levels in mild cognitive impairment and Alzheimer\u2019s disease: a case-control study.","volume":"9","author":"Ma","year":"2017","journal-title":"Nutrients"},{"key":"R28-20260204","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12603-013-0026-7","article-title":"Homocysteine levels and cognitive function scores measured with MMSE and BCAT of middle-aged and elderly subjects in Tianjin City.","volume":"17","author":"Kong","year":"2013","journal-title":"J Nutr Health Aging"},{"key":"R29-20260204","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/archneur.62.4.641","article-title":"Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons.","volume":"62","author":"Morris","year":"2005","journal-title":"Arch Neurol"},{"key":"R30-20260204","first-page":"246","article-title":"A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease.","volume":"1","author":"Paul","year":"2003","journal-title":"Am J Geriatr Psychiatry"},{"key":"R31-20260204","doi-asserted-by":"crossref","first-page":"e17970","DOI":"10.1097\/MD.0000000000017970","article-title":"The relationship between cognitive impairment and homocysteine in a B12 and folate deficient population in China: a cross-sectional study.","volume":"98","author":"Meng","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"R32-20260204","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1073\/pnas.94.11.5923","article-title":"Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor.","volume":"94","author":"Stuart","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"R33-20260204","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1523\/JNEUROSCI.11-01-00147.1991","article-title":"Neurochemical characterization of excitoxin lesions in the cerebral cortex.","volume":"11","author":"Beal","year":"1991","journal-title":"J Neurosci"},{"key":"R34-20260204","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.1993.03510220049033","article-title":"Vitamin status and intake as primary determinants of homocysteinemia in an elderly population.","volume":"270","author":"Selhub","year":"1993","journal-title":"JAMA"},{"key":"R35-20260204","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003495-199448020-00002","article-title":"The clinical potential of adometionine (S-adenosylmethionine) in neurological disorders.","volume":"48","author":"Bottiglieri","year":"1994","journal-title":"Drugs"},{"key":"R36-20260204","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1056\/NEJMoa054025","article-title":"A controlled trial of homocysteine lowering and cognitive performance.","volume":"354","author":"McMahon","year":"2006","journal-title":"N Engl J Med"},{"key":"R37-20260204","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/1028415031000115945","article-title":"Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis.","volume":"6","author":"Besler","year":"2003","journal-title":"Nutr Neurosci"},{"key":"R38-20260204","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/jnnp.2005.072199","article-title":"Plasma homocysteine levels in multiple sclerosis.","volume":"77","author":"Ramsaransing","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R39-20260204","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1136\/jnnp.2008.151555","article-title":"Serum homocysteine levels in relation to clinical progression in multiple sclerosis.","volume":"79","author":"Teunissen","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R40-20260204","doi-asserted-by":"crossref","first-page":"e12244","DOI":"10.1371\/journal.pone.0012244","article-title":"Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.","volume":"5","author":"Smith","year":"2010","journal-title":"PLoS One"},{"key":"R41-20260204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2006.09.002","article-title":"Conversion from cognitive health to mild cognitive impairment and Alzheimer\u2019s disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.","volume":"29","author":"Blasko","year":"2008","journal-title":"Neurobiol Aging"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:01:39Z","timestamp":1770213699000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":37,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038680","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]}}}